High materiality8/10
Zevra Therapeutics price target raised to $35 from $25 at Maxim
Why it may matterVerify against the original reporting
Strong upside potential.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Maxim Group raises ZVRA price target to $35 from $25; current price $13.67.
- Maxim raises ZVRA price target to $35 from $25; current price $13.67.
Key facts
- 01
Target: $35
- 02
Posted price: $13.67
- 03
Analyst firm: Maxim Group
- 04
Analyst: Jason McCarthy
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.